Literature DB >> 12679716

Delayed cerebrovascular protective effect of lipopolysaccharide in parallel to brain ischemic tolerance.

Michèle Bastide1, Patrick Gelé, Olivier Pétrault, Qian Pu, Audrey Caliez, Emmanuel Robin, Dominique Deplanque, Patrick Duriez, Régis Bordet.   

Abstract

Cerebrovascular abnormalities, in endothelium and smooth muscle compartments, occur in the course of cerebral ischemia-reperfusion as evidenced by the impairment of endothelium-dependent relaxation and decrease in potassium inward rectifier density in occluded middle cerebral arteries (MCAs). The authors investigated whether a delayed vascular protection occurred in a model of brain ischemic tolerance. A low dose of lipopolysaccharide (0.3 mg/kg) administered 72 h before MCA occlusion induced a significant decrease in infarct volume. In parallel to this delayed neuroprotective effect, lipopolysaccharide prevented the ischemia-reperfusion-induced impairment of endothelium relaxation. In addition, lipopolysaccharide prevented the postischemic alteration of potassium inward rectifier-dependent smooth muscle relaxation as well as the decrease in potassium inward rectifier density measured by patch-clamp in dissociated vascular smooth muscle cells originated from the occluded MCA. These results suggest that during brain ischemic tolerance, lipopolysaccharide is able to induce both a delayed neuroprotective and vasculoprotective effect.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12679716     DOI: 10.1097/01.WCB.0000050064.57184.F2

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  23 in total

Review 1.  Preconditioning provides neuroprotection in models of CNS disease: paradigms and clinical significance.

Authors:  R Anne Stetler; Rehana K Leak; Yu Gan; Peiying Li; Feng Zhang; Xiaoming Hu; Zheng Jing; Jun Chen; Michael J Zigmond; Yanqin Gao
Journal:  Prog Neurobiol       Date:  2014-01-02       Impact factor: 11.685

Review 2.  Toll-like receptor signaling in endogenous neuroprotection and stroke.

Authors:  B J Marsh; R L Williams-Karnesky; M P Stenzel-Poore
Journal:  Neuroscience       Date:  2008-08-12       Impact factor: 3.590

Review 3.  Smooth Muscle Ion Channels and Regulation of Vascular Tone in Resistance Arteries and Arterioles.

Authors:  Nathan R Tykocki; Erika M Boerman; William F Jackson
Journal:  Compr Physiol       Date:  2017-03-16       Impact factor: 9.090

Review 4.  Potassium Channels in Regulation of Vascular Smooth Muscle Contraction and Growth.

Authors:  W F Jackson
Journal:  Adv Pharmacol       Date:  2016-08-17

5.  Protective conditioning of the brain: expressway or roadblock?

Authors:  Philipp Mergenthaler; Ulrich Dirnagl
Journal:  J Physiol       Date:  2011-06-27       Impact factor: 5.182

6.  Effects of the PPAR-α agonist fenofibrate on acute and short-term consequences of brain ischemia.

Authors:  Thavarak Ouk; Sophie Gautier; Maud Pétrault; David Montaigne; Xavier Maréchal; Isabelle Masse; Jean-Christophe Devedjian; Dominique Deplanque; Michèle Bastide; Rémi Nevière; Patrick Duriez; Bart Staels; Florence Pasquier; Didier Leys; Régis Bordet
Journal:  J Cereb Blood Flow Metab       Date:  2014-01-08       Impact factor: 6.200

7.  Pharmacologic preconditioning: translating the promise.

Authors:  Jeffrey M Gidday
Journal:  Transl Stroke Res       Date:  2010-01-03       Impact factor: 6.829

8.  Preconditioning-induced ischemic tolerance: a window into endogenous gearing for cerebroprotection.

Authors:  Aysan Durukan; Turgut Tatlisumak
Journal:  Exp Transl Stroke Med       Date:  2010-01-21

Review 9.  Toll-like receptors: novel pharmacological targets for the treatment of neurological diseases.

Authors:  Brenda J Marsh; Mary P Stenzel-Poore
Journal:  Curr Opin Pharmacol       Date:  2007-11-05       Impact factor: 5.547

Review 10.  Toll-like receptors in central nervous system glial inflammation and homeostasis.

Authors:  Tammy Kielian
Journal:  J Neurosci Res       Date:  2006-04       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.